VYNE Therapeutics (VYNE) Current Deferred Revenue (2016 - 2018)

VYNE Therapeutics' Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $1.8 million for Q1 2018.

• Quarterly Current Deferred Revenue changed N/A year-over-year to $1.8 million in Q1 2018, while the trailing twelve-month figure through Mar 2018 was $1.8 million (changed N/A YoY) and the FY2017 annual result came in at $1.8 million, changed 0.0% from the prior year.
• Current Deferred Revenue was $1.8 million for Q1 2018 at VYNE Therapeutics, roughly flat from $1.8 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $1.8 million in Q4 2016 and bottomed at $1.8 million in Q4 2016.
• A 3-year average of $1.8 million and a median of $1.8 million in 2016 frame the typical range for Current Deferred Revenue.
• Peak annual rise in Current Deferred Revenue reached 0.0% in 2017, while the deepest fall reached 0.0% in 2017.
• VYNE Therapeutics' Current Deferred Revenue stood at $1.8 million in 2016, then changed by 0.0% to $1.8 million in 2017, then changed by 0.0% to $1.8 million in 2018.
• Business Quant data shows VYNE's Current Deferred Revenue at $1.8 million in Q1 2018, $1.8 million in Q4 2017, and $1.8 million in Q4 2016.